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ABSTRACT 
Rationale: To investigate the performance of high-resolution computed tomography 
(HRCT) versus 18F-FDG-PET/CT for the diagnosis of pulmonary lymphangitic 
carcinomatosis (PLC). 
Methods: In this retrospective institutional approved study, ninety-four patients addressed 
for initial staging of lung cancer with suspicion of PLC were included. Using double blind 
analysis, we assessed the presence of signs favoring PLC on HRCT (smooth or nodular 
septal lines, subpleural nodularity, peribronchovascular thickening, satellite nodules, 
lymph node enlargement and pleural effusion). 18F-FDG-PET/CT images were reviewed 
to qualitatively evaluate peritumoral uptake and to quantify tracer uptake in the tumoral 
and peritumoral areas. Histology performed on surgical specimens served as gold 
standard in all patients. 
Results: Among 94 included patients, 73% (69/94) had histologically confirmed PLC. 
Peribronchovascular thickening, lymph nodes involvement and increased peritumoral 
uptake were more often present in patients with PLC (p<0.009). Metabolic variables 
including tumor SUVmax, SUVmean, “metabolic tumor volume” (MTV) and total lesion 
glycolysis (TLG) as well as peritumoral SUVmax, SUVmean and their respective ratios to 
background were significantly higher in PLC group versus the non-PLC group (p≤0.0039). 
Sensitivity, specificity, and ROC area [95%CI] of peribronchovascular thickening (69%, 
83% and 0.76 [0.67–0.85]) and increased peritumoral uptake (94%, 84% and 0.89 [0.81–
0.97]) were similar (p=0.054). Peritumoral SUVmax and SUVmean had a significantly 
higher sensitivity, specificity, and ROC area of 97%, 92% and 0.98 [0.96–1.00] and 94%, 
88% and 0.96 [0.92–1.00] for detecting PLC (all p≤0.025). 
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Conclusion: Qualitative evaluation of 18F-FDG-PET/CT and HRCT have similar 
performance for the diagnosis of PLC, both being outperformed by 18F-FDG-PET/CT 
quantitative parameters. 
Keywords: Pulmonary lymphangitic carcinomatosis, lung cancer, PET/CT, FDG, HRCT. 
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INTRODUCTION 
Pulmonary lymphangitic carcinomatosis (PLC) was first described by Troisier in 1873 and 
is morphologically defined by the presence of malignant cells within pulmonary vessels, 
in particular the lymphatics. (1) Mainly originating from adenocarcinoma of the breast, 
stomach, lung, pancreas, and prostate, PLC may appear as bilateral symmetric pattern 
in case of hematogenous spread through the pulmonary arteries and subsequently into 
the perivascular interstitium and lymphatic vessels or as an asymmetric localized pattern 
with direct extension from primary lung tumor, hilar lymph nodes or pleura. (2) Even 
though definitive diagnosis of PLC requires lung biopsy, high resolution computed 
tomography (HRCT) is considered as an essential tool in the diagnostic process and is 
recommended to be performed prior to pathologic examination. (3-5) The few studies that 
investigated the role of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-
PET/CT) in the diagnosis of PLC, suggest an effective and reliable role of PET/CT as a 
non-invasive technique allowing PLC identification with high specificity. (6-8) Regarding 
the diagnostic performance of 18F-FDG-PET/CT, data still remain spare compared to 
HRCT, and no study formally evaluated the diagnostic value of quantitative PET/CT 
metrics compared to HRCT and PET/CT qualitative evaluations. We hence hypothetized 
that measure of 18F-FDG uptake in the peritumoral lung may help to detect PLC in patients 
with primary lung cancer.  
The aim of this study was thus to investigate the diagnostic performance of HRCT versus 
18F-FDG-PET/CT for the diagnosis of PLC secondary to lung cancer using the histologic 
gold standard, as well as to evaluate the added value of quantitative 18F-FDG-PET/CT 
metrics. 
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MATERIALS AND METHODS 
Study Design 
The study was conducted according to Standards for Reporting of Diagnostic Accuracy 
Studies 2015 guidelines. (9) All patients referred to our Institutional Thoracic Cancer 
Board from December 2012 to May 2016 after initial staging of untreated lung cancer 
were retrospectively reviewed. Inclusion criteria were as follows: 1) patients who had both 
HRCT and 18F-FDG-PET/CT for initial staging within 10 weeks, 2) patients who underwent 
surgical resection (i.e segmentectomy, lobectomy or pneumectomy) without neoadjuvant 
chemotherapy. Exclusion criteria were as follows: 1) patients who underwent HRCT and 
18F-FDG-PET/CT with a delay longer than 10 weeks, 2) 18F-FDG-PET/CT not performed 
in our institution, 3) patients who underwent neoadjuvant chemotherapy (Fig. 1). PLC, as 
defined by the presence of secondary invasive cells within the vessels in the peritumoral 
area, was ascertained on pathology reports that were used as our gold standard. For all 
included patients, the presence of imaging signs of PLC was evaluated on HRCT and 
18F-FDG-PET/CT based on a double blinded study and correlated to clinical pathology, 
with less than 10 weeks (median delay: 3.5 weeks, range 0.1-10 weeks) intervening 
between the two modalities. The local Ethics Research Committee of the State of Vaud 
approved the research protocol (CER-VD #2016-01295) and, considering the 
retrospective nature of this study, waived the need for obtaining patient informed consent. 
18F-FDG-PET/CT Acquisition and Analysis 
Patients underwent 18F-FDG-PET/CT on a Discovery D690 TOF (GE Healthcare, 
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Milwaukee, WI) 50–70 minutes after a planned intravenous injection of 3.70.5 MBq/kg 
of 18F-FDG. All patients fasted for at least 6 hours and had blood glucose levels lower 
than 140 mg/dl before administration of 18F-FDG. A low-dose helical CT (tube voltage: 
120–140kV, tube current: 80–200mA automodulation, pitch 1.375, 0.8 sec/rotation, 3.75-
mm slice thickness) was first performed for anatomical correlation and attenuation 
correction. Raw data were reconstructed using a blend of 40% of adaptive statistical 
iterative reconstruction and 60% of filtered-back-projection (FBP). Then, whole-body 
emission images were acquired using 7–9 overlapping bed positions of 2 min each 
(starting from the top of skull and ending at the mid-thigh). Images were reconstructed 
using ordered subset expectation maximization protocol (8 subsets, 2 iterations) with 
body weight-normalized SUV computation. 
For each patient, SUVmax (g/ml), SUVmean (g/ml), metabolic tumoral volume (MTV) 
(cm3) and total lesion glycolysis (TLG) (g*cm3/ml) of the primary lung tumor were 
measured using a standard 42% SUVmax threshold volume-of-interest (VOI) embedding 
the whole tumor. In addition, perilesional tumoral activity was visually assessed (not 
increased=0, increased=1 as compared to contralateral normal lung) and quantified with 
measurement of peritumoral SUVmax and SUVmean within a peritumoral range of 3 cm 
using a VOI of 3 cm3 on the most active region. Normal lung background uptake, as 
defined by SUVmean measured in a 3 cm3 VOI within the contralateral normal lung, was 
used to calculate peritumoral uptake ratios as followed: peritumoral SUVmax ratio = 
peritumoral SUVmax / contralateral normal lung SUVmean. Peritumoral SUVmax and 
SUVmean measures were performed twice by two nuclear physicians with 4-years and 
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10-years of experience, blinded for histological results, to assess inter-observer 
reproducibility. 
HRCT Acquisition and Analysis 
Thoracic HRCT were performed on multiple vendor multidetector CT scanners. Due to 
the retrospective nature of the study, CT acquisition protocols were variables for dose 
parameters (tube voltage: 80–120 kV, tube intensity: 80–400 mA or mA automodulation). 
All raw data were reconstructed by FBP using soft and lung kernel with 1-mm slice 
thickness. 
HRCT images of the 94 included patients were analyzed by two radiologists with 
respectively 25 and 10 years of experience in thoracic imaging, blinded for histological 
results and in consensus. The presence of smooth lines (0=absent, 1=present), nodular 
septal lines (0=absent, 1=present), subpleural nodularity (0=absent, 1=present), 
peribronchovascular thickening (0=absent, 1=present), satellite nodules (0=absent, 
1=present), lymph node enlargement (0=absent, 1=present), pleural effusion (0=absent, 
1=present) and enlarged pulmonary veins (0=absent, 1=present) adjacent to the primary 
lung tumor were recorded at the patient level. 
Histological Analysis 
All surgical specimens were prospectively analyzed by a pathologist with more than 15 
years of experience in thoracic pathology and retrospectively collected. The pathologist 
was blinded to imaging results at the time of histological analysis. Resected lung 
specimens were fixed in formalin for 24–48 hours. Representative samples of the tumor 
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were taken, embedded in paraffin, and the slides were stained with hematoxylin and 
eosin. PLC was defined by the presence of secondary invasive cells within the vessels in 
the peritumoral area. Tumor typing was performed according to the 2011 IASLC / 2015 
WHO classification. (10) 
Statistical Analyses 
All statistical analyses were performed using STATA version 15.1 (STATA Corp., College 
Station, TX, USA). Sample size calculation was performed to test equality of HRCT as 
compared to 18F-FDG-PET/CT. On the basis of the previous study by Prakash et al. we 
considered an accuracy of 93% for 18F-FDG-PET/CT, and a difference of 10% between 
the two methods. (6) We calculated a sample size of 93 patients to achieve an 80% power 
by using two-sided McNemar test at a significance level  of 0.05. Continuous variables 
are presented as mean ± standard deviation or median (interquartile range [IQR]). 
Categorical variables are presented as number or percentage. Histological outcome was 
used as gold standard for the diagnosis of PLC. All collected variables derived from the 
analysis of HRCT and 18F-FDG-PET/CT were then compared between patients with and 
without PLC using the Kruskal-Wallis test for continuous variables and Fisher exact test 
for categorical variables. Inter-observer reproducibility of peritumoral SUVmax and 
SUVmean was assessed by the Pearson’s correlation coefficient () and the Lin’s 
concordance correlation coefficient (c=  x Cb, Cb measuring systematic bias). (11) The 
association between imaging variables and PLC was assessed using logistic regression 
analysis with computation of respective odds ratios (OR) and 95% confidence intervals 
(95%CI). Odds ratios of significant predictors were compared using the Hausman’s 
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specification test. Receiver operating characteristics (ROC) curve analysis was also 
performed with computation of ROC area, sensitivity, specificity, positive and negative 
likelihood ratio and respective 95%CI for each variable. For continuous variables, optimal 
cut-off values allowing detection of patients with PLC were determined by the Liu method. 
(12) ROC areas comparison was done for HRCT and 18F-FDG-PET/CT variables that 
were significantly associated to PLC on univariate logistic regression analysis (i.e. 
peribronchovascular thickening, increased peritumoral uptake and peritumoral SUVmax 
and SUVmean) using the non-parametric Chi-squared test of equality of ROC curves’ 
areas, as defined by DeLong et al. (13) For this, we used multiple imaging parameters on 
univariate analysis, the significance level was corrected by the Bonferroni method to 
account for multiple testing. P values <0.003 were considered as statistically significant. 
RESULTS 
Study Population 
Overall, 94 patients (67 males, 27 females, median age 68 years, range 44-87 years) 
were retrospectively included (Table 1). All underwent surgical resection and histological 
analysis of surgical specimens 5.9 weeks (range 0.6-22.8 months) after initial imaging 
evaluation. Of the 94 patients, 29 patients had stage 1 disease, 29 patients had stage 2 
disease, 34 patients had stage 3 disease and 2 patients had stage 4 disease according 
to the 8th edition of the TNM classification for lung cancer. (14) Six patients underwent a 
pneumonectomy, 81 patients a lobectomy and 7 patients a segmentectomy. Fifty-five 
patients had adenocarcinoma, 34 patients had squamous cell carcinoma and 5 patients 
had poorly differentiated non-small cell carcinoma. Histological analysis additionally 
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confirmed PLC in 69/94 patients (73%). 
Qualitative HRCT and 18F-FDG-PET/CT Analyses 
All HRCT results are displayed in Table 1. There was no missing data for both imaging 
methods. Only peribronchovascular thickening (Fig. 2) was significantly correlated with 
the presence of PLC (OR=10.95, 95%CI:3.33–36.0, p<0.001, Table 2) and showed a 
ROC area, sensitivity, specificity, positive and negative likelihood ratios of 0.76 
[95%CI:0.67–0.85], 69%, 83%, 4.12 and 0.38. The presence of increased peritumoral 
uptake in comparison to lung background had similar performance to peribronchovascular 
thickening with a ROC area, sensitivity and specificity of 0.89 [95%CI:0.81–0.97], 94% 
and 84% (p=0.054, Table 3). 
Quantitative 18F-FDG-PET/CT Analysis 
The inter-observer reproducibility of peritumoral SUVmax (=0.922, c=0.921, Cb=1.0) 
and SUVmean (=0.850, c=0.850, Cb=1.0) measurement was excellent. Metabolic 
variables including tumor TLG as well as peritumoral SUVmax, SUVmean and their 
respective ratios to background were significantly higher in patients with PLC compared 
to patients without PLC on surgical specimens (p=0.0006, p=0.0001, p=0.0001, p=0.0001 
and p=0.0001, respectively, Table 1). Peritumoral SUVmax and SUVmean but not 
tumoral quantitative parameters were highly associated with PLC (Fig.3 and Table 3). 
Peritumoral SUVmax and SUVmean OR were significantly higher than OR of qualitatively 
increased peritumoral uptake (p=0.0022 and p=0.0005) and than OR of 
peribronchovascular thickening (p=0.0004 and p<0.0001). Peritumoral SUVmax with a 
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cut-off of 2.1 g/ml had a significantly higher sensitivity, specificity, and ROC area of 97%, 
92% and 0.98 [95%CI:0.96-1.00] for detecting PLC compared to both qualitatively 
increased peritumoral uptake (p=0.0064) and peribronchovascular thickening (p<0.0001, 
Fig. 4). Peritumoral SUVmean with a cut-off of 1.2 g/ml also had higher performance for 
detecting PLC compared to increased peritumoral uptake (p=0.025) and 
peribronchovascular thickening (p<0.0001). The diagnostic performance of absolute 
peritumoral SUVmax, peritumoral SUVmean, peritumoral SUVmax ratio and peritumoral 
SUVmean ratio were similar (p≥0.10). 
DISCUSSION  
In this study, we showed that 18F-FDG-PET/CT and HRCT had similar performance for 
the diagnosis of PLC in patients addressed for initial staging of primary lung tumor when 
respectively qualitatively evaluating increased peritumoral uptake and 
peribronchovascular thickening. Other signs such as smooth or nodular septal lines, 
subpleural nodularity, satellite nodules, or pleural effusion were not significantly 
associated with PLC. Moreover, 18F-FDG uptake quantification in the peritumoral area 
outperformed qualitative analysis of both modalities. 
The pathogenesis of pulmonary tumor embolism and lymphangitic carcinomatosis is 
poorly understood. It is thought that in PLC tumor cells gain access to the lung vascular 
system – and particularly to the lymphatic system – to induce local tumoral spread via 
neovasculature or neolymphatics in case of lung primary. In the case of non-pulmonary 
primary tumors, the cells spread via retrograde flow since the majority of these 
malignancies involve thoracic lymph nodes. Invasion of the interstitial space by tumor 
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cells or in distended lymphatic vessels can result in thickened peribronchovascular 
bundles and septa. (15-17) Tumor cells trapped within lymphatics result in local 
obstruction and fluid accumulation. Thus, peribronchovascular bundle and alveolar septal 
thickening may be due to local edema. (1) Any malignant tumor has the potential to result 
in pulmonary tumor embolism, whether as PLC or as pulmonary tumor emboli, with higher 
incidence in patients with renal cell and hepatocellular carcinoma as well as 
adenocarcinoma of the breast, stomach, colon, and lung. (18, 19) This pattern of tumor 
spread is not common and occurs in less than 10% of metastatic cancers in the lung. (2) 
The definitive diagnosis of PLC depends upon the identification of tumor cells in the 
pulmonary lymphatics on histological examination, which allows identifying obstruction 
and distension of pleural, peribronchial, perivascular or subpleural lymphatics. (17) PLC 
is typically an advanced-stage manifestation of malignancy and is associated with poor 
prognosis. (20-22).  
Common findings associated with PLC on HRCT include thickening of interlobular septa 
and peribronchovascular interstitium, sub-pleural nodules, thickening of the interlobar 
fissures, pleural effusion, pleural carcinomatosis, hilar and mediastinal nodal enlargement 
with relatively little destruction of overall lung architecture. (4) However, smooth or 
thickened interlobular septa on HRCT, in particular with nodular appearance are not being 
specific for PLC since it is also encountered in other interstitial disorders such as 
sarcoidosis (23) Hilar adenopathy and effusions were occasionally present in reported 
series of PLC. (24)  
In a retrospective study on 21 patients, when correlated to pathology, certain 
characteristic findings on CT scans were evident: uneven thickening of 
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peribronchovascular bundles, thickening of isolated interstitial lines, and the presence of 
polygonal lines. The pathologic basis for these characteristic CT findings was considered 
by the authors as related to tumor thrombi in lymphatic vessels rather than edema and 
fibrosis, at least in the early stages of disease. (25) Another study reported that thickening 
of peribronchovascular bundles and interlobular septa is the single most important chest 
CT finding of pulmonary lymphangitic carcinomatosis. (26) Our study hereby confirms that 
peribronchovascular thickening and lymph node enlargement should mainly be 
considered as signs of PLC at initial staging, while first reporting diagnostic performance 
parameters of HRCT in this setting.  
Regarding 18F-FDG-PET/CT, we described the largest series of patients with 
histologically proven PLC and who underwent imaging with a state-of-the art 18F-FDG-
PET/CT scanner. To the best of our knowledge, only three studies reported on the role of 
18F-FDG-PET/CT in the diagnosis of PLC. In a retrospective study of 35 patients, Prakash 
et al. found a high specificity of 100% of 18F-FDG-PET/CT in the detection of PLC with a 
sensitivity of 86%. (6) In addition, this study reported a statistically significant increased 
18F-FDG uptake in the PLC areas in contrast to normal lung parenchyma and blood pool 
activity, in concordance with our results. In a group of 7 patients with PLC, Digumarthy et 
al. reported that the intensity of 18F-FDG uptake in diseased lung is significantly greater 
than in corresponding normal contralateral lung or in the lungs of normal controls with a 
ratio of the SUV of lung with lymphangitic carcinomatosis to corresponding contralateral 
normal lung significantly increased. (8) In a series of five PLC positive cases, Acikgoz et 
al. described the 18F-FDG-PET/CT pattern, varying from a diffuse, lobar, or segmental 
18F-FDG uptake in the lungs in extensive PLC to a hazy area of 18F-FDG uptake or linear 
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uptake extending from the tumor to the lymph nodes in limited PLC. The route of 
lymphangitic spread in these cases was considered either through seeding of tumor cells 
to the peribronchovascular lymphatics or direct invasion of lymphatics by the lung tumor. 
(7) While we confirm that increased peritumoral uptake may be useful for the detection of 
PLC, its performance is not superior to peribronchovascular thickening on HRCT. 
Moreover, we first demonstrate that adding peritumoral SUV and ratio to lung background 
measurement significantly improve the performance of 18F-FDG-PET/CT for the 
diagnosis of PLC. Quantitative 18F-FDG-PET/CT of peritumoral areas should hence be 
part of the initial imaging workup of patients with primary lung cancer. It is however worthy 
to mention that CT images should always be checked before measuring peritumoral SUV 
in order to avoid misinterpretation of peritumoral infiltrates from another etiology such as 
infection (27). In the area of hybrid imaging, acquisition of HRCT images during a single 
contrast enhanced 18F-FDG–PET/HRCT examination should be the next step to optimize 
patients’ evaluation and minimize costs. This has to be evaluated further. 
We have to address some limitations of our study. First, due to its retrospective nature, 
HRCT images were acquired on multiple vendor CT scanners with variable acquisition 
parameters but similar reconstruction parameters. Although image quality may be 
different, it reflects daily practice of our thoracic oncology board. Second, HRCT images 
were assessed by experts in thoracic imaging. While qualitative evaluation of HRCT and 
18F-FDG-PET/CT demonstrated similar performance, the learning curve to detect subtle 
peribronchovascular thickening on HRCT may be an issue to reproduce this result in daily 
practice, especially in situations such as COPD patients with bronchial wall thickening. 
Third, only patients who underwent surgical resection were included. While this allowed 
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histological confirmation of PLC, reported cut-off values of quantitative metrics may not 
be fully transposable in inoperable patients, as it may not be transposable using different 
PET scanner or reconstruction algorythm. However, use of peritumoral SUV ratios may 
overwhelm this limitation, with similar diagnostic confidence. Finally, while the use of 18F-
FDG-PET/CT quantitative parameters improved the diagnostic performance of 18F-FDG-
PET/CT for PLC, the prognostic value of these metrics at initial staging remains unknown. 
This was out of the scope of the present study and should be further assessed to fully 
evaluate the usefulness of these measurements. 
CONCLUSION 
Our study showed that peribronchovascular thickening and increased peritumoral tracer 
uptake, respectively on HRCT and 18F-FDG-PET/CT, have similar performance for the 
diagnosis of PLC in patients with lung cancer at initial staging. Peritumoral 18F-FDG 
uptake quantification however outperformed qualitative evaluation. Combining resultant 
morphologic and metabolic criteria may thus help to establish a powerful tool for the 
diagnosis of PLC. 
DISCLOSURE 
The authors have no potential conflict of interest to report. 
17
KEY POINTS 
QUESTION: To compare the performance of HRCT versus 18F-FDG-PET/CT for the 
diagnosis of pulmonary lymphangitic carcinomatosis (PLC). 
PERTINENT FINDINGS: Peribronchovascular thickening and increased peritumoral 
tracer uptake, respectively on HRCT and 18F-FDG-PET/CT, have similar performance for 
the diagnosis of pulmonary lymphangitic carcinomatosis in patients with lung cancer at 
initial staging. 
Peritumoral 18F-FDG uptake quantification however outperforms qualitative evaluation on 
both modalities. 
IMPLICATIONS FOR PATIENT CARE: Combining morphologic and metabolic 
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FIGURE 1. Study flowchart. 
ITCB= Institutional Thoracic Cancer Board, PLC= pulmonary lymphangitic 
carcinomatosis 
23
FIGURE 2. Case of a 66-year-old female referred for initial staging of inferior lobe 
pulmonary adenocarcinoma (Stage IIIA). HRCT (A) shows positive peribronchovascular 
thickening sign (yellow arrow) and 18F-FDG-PET/CT (B) shows 18F-FDG uptake in the 
corresponding region higher than background, with a SUVmax of 2.5 g/ml and a SUVmax 
to background ratio of 3.6. 
24
FIGURE 3. Boxplot showing a significant difference of SUVmax values in the peritumoral 
region on 18F-FDG-PET/CT in patients with (PLC+) and without PLC (PLC–). 
25
FIGURE 4. ROC curves comparing the performance of peribronchovascular thickening 
on HRCT (red line, ROC area=0.76 [0.67–0.85]) and SUVmax in the peritumoral region 




TABLE 1. Clinico-pathological characteristics and results of HRCT and 18F-FDG-PET/CT 








Age 67±10 66±9 0.81 




























Poorly differentiated NSCLC 









Smooth lines 19 60 0.45 
Nodular lines 3 13 0.62 
Peribronchovascular thickening 4 46 0.0002 
Subpleural space 3 4 0.64 
Satellite nodes 6 12 0.61 
Enlarged lymph nodes 7 44 0.0082 
Pleural effusion 3 9 0.95 
Enlarged pulmonary veins 4 4 0.44 
 PET Qualitative 
Peritumoral increased uptake 4 65 0.0001 
PET Quantitative 
Tumor SUVmax (g/mL) 9.1±7.1 14.1±8.0 0.0031 
Tumor SUVmean (g/mL) 5.5±4.7 8.4±5.1 0.0039 
MTV (cm3) 9.6±9.4 22.3±23.3 0.0031 
TLG (g.cm3/mL) 72.9±119.4 225.8±322.7 0.0006 
Peritumoral SUVmax (g/mL) 1.5±0.4 3.2±0.6 0.0001 
Peritumoral SUVmean (g/mL) 0.9±0.3 1.8±0.4 0.0001 
Peritumoral SUVmax ratio (1) 1.6±0.5 3.2±0.7 0.0001 
Peritumoral SUVmean ratio (1) 1.7±0.6 3.1±0.9 0.0001 
HRCT= high-resolution computed tomography, MTV= metabolic tumoral volume, 
NSCLC= non-small cell lung carcinoma, PET= positron emission tomography, PLC= 
pulmonary lymphangitic carcinomatosis, SUV= standardized uptake value, TLG= total 
lesion glycolysis, TNM=tumor node metastasis. P-values were obtained using the 
27
Kruskal-Wallis test for continuous variables and Fisher exact test for categorical 
variables. For imaging parameters, P values <0.003 were considered statistically 
significant to account for multiple comparisons. 
28
TABLE 2. Results of association of HRCT variables with PLC: odds ratios (OR) with 95% 
confidence interval, as well as ROC area, sensitivity (Se), specificity (Sp), positive and 
negative likelihood ratios (LR+ and LR-) with 95% confidence interval. 
HRCT= high resolution computed tomography, PLC= pulmonary lymphangitic carcinomatosis. 
P values <0.003 were considered statistically significant to account for multiple testing. 










































































































































































TABLE 3. Results of association of 18F-FDG-PET/CT variables with PLC: odds ratios (OR) 
with 95% confidence interval, as well as ROC area, cut-off values determined by the Liu 
method, sensitivity (Se), specificity (Sp), positive and negative likelihood ratios (LR+ and 








































































































































































































MTV= metabolic tumor volume, PET= positron emission tomography, PLC= pulmonary 
lymphangitic carcinomatosis, SUV= standardized uptake value, TLG= total lesion 
glycolysis, TNM=tumor node metastasis. P values <0.003 were considered statistically 
significant to account for multiple testing. 
